Stockreport

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment [Yahoo! Finance]

Cocrystal Pharma, Inc.  (COCP) 
NASDAQ:AMEX Investor Relations: cocrystalpharma.com
PDF Cocrystal Pharma, Inc. CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of [Read more]